Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M439Revenue (TTM) $M22.0Net Margin (%)-313.0Altman Z-Score-7.3
Enterprise Value $M440EPS (TTM) $-0.9Operating Margin %-262.2Piotroski F-Score2
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-313.0Higher ROA y-yN
Price/Book11010-y EBITDA Growth Rate %-7.2Quick Ratio1.2Cash flow > EarningsY
Price/Sales20.05-y EBITDA Growth Rate %-10.7Current Ratio1.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-63.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-219.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M73.8ROIC % (ttm)-329.0Gross Margin Increase y-yY

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXJohn Paulson 2016-09-30 Add0.01%$2.87 - $5.04
($3.99)
$ 5.9549%Add 38.01%363,100
BCRXJohn Paulson 2016-03-31 Buy 0.01%$1.66 - $10.32
($4.53)
$ 5.9531%New holding263,100
BCRXJoel Greenblatt 2016-03-31 Sold Out $1.66 - $10.32
($4.53)
$ 5.9531%Sold Out0
BCRXJoel Greenblatt 2015-12-31 Buy $8.28 - $12.44
($9.93)
$ 5.95-40%New holding19,424
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 5.95-39%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 5.95-44%New holding59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STAAB THOMAS R IISenior Vice President and CFO 2016-12-19Sell3,250$7.45-20.13view
Barnes Alane PVP, General Counsel & Corp Sec 2016-09-14Sell8,357$4.2739.34view
Babu Yarlagadda SSenior VP - Drug Discovery 2016-08-25Sell30,000$4.0646.55view
BAKER BROS. ADVISORS LP10% Owner 2016-08-16Sell4,046,590$519view
STAAB THOMAS R IISenior Vice President and CFO 2016-08-12Sell5,864$5.1814.86view
STAAB THOMAS R IISenior Vice President and CFO 2016-08-09Sell14,577$4.4334.31view
BAKER BROS. ADVISORS LP10% Owner 2016-02-05Buy45,000$6.33-6view
BAKER BROS. ADVISORS LP10% Owner 2016-02-04Buy207,715$6.43-7.47view
BAKER BROS. ADVISORS LP10% Owner 2016-01-28Buy88,345$6.95-14.39view
BAKER BROS. ADVISORS LP10% Owner 2016-01-22Buy106,800$7.28-18.27view

Quarterly/Annual Reports about BCRX:

News about BCRX:

Articles On GuruFocus.com
A Trump Presidency May Be Good for Biotech Dec 16 2016 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
BioCryst Receives Health Canada Approval for RAPIVAB® for the Treatment of Influenza Jan 08 2017
BioCryst to Present at the J.P. Morgan Healthcare Conference Jan 04 2017
Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)? Dec 29 2016
Are Options Traders Betting on a Big Move in BioCryst (BCRX) Stock? Dec 22 2016
A Trump Presidency May Be Good for Biotech Dec 16 2016
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 16, 2016 Dec 16 2016
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 5, 2016 Dec 05 2016
What Smart Money Thinks about BioCryst Pharmaceuticals, Inc. (BCRX)? Dec 05 2016
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22,... Nov 22 2016
BioCryst to Present at the Piper Jaffray Healthcare Conference November 30 Nov 17 2016
BIOCRYST PHARMACEUTICALS INC Financials Nov 16 2016
How investors are playing Biocryst Nov 10 2016
ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : November 9, 2016 Nov 09 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 08 2016
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US :... Nov 08 2016
Edited Transcript of BCRX earnings conference call or presentation 7-Nov-16 4:00pm GMT Nov 07 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 07 2016
Q3 2016 BioCryst Pharmaceuticals Inc Earnings Release - Before Market Open Nov 07 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)